Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

• Status: Terminated
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objectives of the project are:

• To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI)

• To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Norwegian University of Science and Technology
• Treatments: Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• moderate to severe plaque psoriasis for more than six months

• eligible for efalizumab treatment according to current Norwegian guidelines

Exclusion Criteria:

• Pregnant or breast-feeding patients

• Patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.

• Patients suffering from HIV, Hepatitis B or C, active tuberculosis, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year.

• Patients with history of cancer in the preceding 5 years, including lymphoproliferative disorders. patients with history of fully resolved basal cell or squamous cell skin cancer may be enrolled.

• Patients with impaired renal or hepatic function.